Myriad Genetics Reports Q3 2026 Revenue of $202.7M, GAAP EPS of -$0.46 Misses Estimates

Prenatal Health Divestiture to Labcorp for $210 Million Reshapes Portfolio Around Cancer Care Continuum Related Stocks: MYGN ,

Read original article